Scott Braunstein, Marinus CEO (Marinus via YouTube)
September 14, 2020 04:01 PM EDTUpdated September 15, 06:24 AM
R&D
FDA+

Mar­i­nus ex­ecs her­ald the re­birth of the one-drug biotech as a pos­i­tive PhI­II read­out ar­rives for a rare dis­ease

John Carroll

Editor & Founder

Af­ter a long, neck-snap­ping ride full of spills, thrills and dis­mal chills, the ex­ecs now run­ning small-cap biotech Mar­i­nus $MRNS say they …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Trump ad­min­is­tra­tion halts more than $750M in funds for Mod­er­na’s bird flu vac­cine

A new dawn for psy­che­delics? Com­pass could be the first to find out

The fate of Mod­er­na’s next-gen Covid shot looms large af­ter a flur­ry of pol­i­cy changes

Up­dat­ed: MD An­der­son-al­lied in­vest­ment firm tar­gets $250M for sec­ond can­cer biotech fund

No­vo Nordisk ‘strong­ly’ urges against phar­ma tar­iffs as com­ments flood in

sponsored

From weeks to days: how Aizon In­tel­li­gent Agents trans­form phar­ma val­i­da­tion

A service from the Financial Times